RCS - Abingdon Health PLC - AppDx® granted further patent

Abingdon HealthAnnouncement

07/03/2023 07:00

For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20230307:nRSG0713Sa&default-theme=true

RNS Number : 0713S  Abingdon Health PLC  07 March 2023

 

Abingdon Health plc

("Abingdon Health" or "the Company")

 

AppDx(®) lateral flow smartphone reader granted further patent

 

York, U.K. 7 March 2023: Abingdon Health plc (AIM: ABDX), a leading
international lateral flow contract development and manufacturing organisation
(CDMO), announces the granting of an additional patent for its AppDx® lateral
flow smartphone reader.

 

AppDx® is a software development kit (SDK) for reading colorimetric
lateral-flow tests (LFT) organized for Android™ and iOS® smartphone
operating systems. AppDx® enables lateral-flow test readout from your pocket,
enabled by a smartphone camera, that can be used by any user app. It consists
of a software Application Programming Interface (API) accessed as a library
which contains algorithms for image processing and deep learning in order to
read a lateral-flow test using a smartphone. The algorithms need to be
customized and tuned for each test. The Abingdon Health AppDx® algorithm
reads the lateral flow device qualitatively (e.g. positive/negative) and
semi-quantitively (e.g. negative/high/medium/low). A key point of
differentiation is that the algorithm may be located on the smartphone,
therefore not requiring a Wifi connection or 4G connection. It can also be
provided as a web server-based solution.

 

The granted patent (GB 2601978) relates to the use of a plurality of captured
images to provide a more refined algorithm which allows variations in imaging
conditions to be averaged out and/or outliers removed. This allows the
algorithm to counteract typically seen issues with measuring lateral flow
devices such as specks of dust, reflections other artefacts and importantly
different lighting conditions. These are important factors when considering
the use of lateral flow tests in a range of different environments such as the
home, doctor's office, veterinary office, farm or field. This innovation
therefore is of critical importance in enabling the application of AppDx®
commercially across a range of applications.

 

This is the third patent granted to Abingdon Health in relation to AppDx®,
including the granting of patent GB 2583419 which covers the use of
neural-network based detection of lateral-flow tests, extracting the
region-of-interest, and processing the data to calculate the values of the
assay lines. This covers the two-stage pipeline where the assay area is
extracted from the picture and image processing algorithms measure the line
values and positions.

 

Chris Yates, CEO of Abingdon Health plc, commented: "We are pleased to
announce the granting of a further patent for our AppDx® smartphone lateral
flow reader. Given the expected rapid growth in the lateral flow self-test
market we believe the use of smartphone apps, such as AppDx®, will be
critical in allowing widespread adoption of lateral flow rapid-testing.

 

"This patent grant underlines Abingdon's focus on innovation to support its
customers and we now look forward to initiating commercial discussions to
bring this product to market."

 

 

Enquiries

 

 Abingdon Health plc                                          www.abingdonhealth.com/investors/ (http://www.abingdonhealth.com/investors/)
 Chris Yates, Chief Executive Officer                         Via Walbrook PR
 Melanie Ross, Chief Financial Officer
                                  Tel: +44 (0)20 7933 8780 or abingdon@walbrookpr.com

                                (mailto:abingdon@walbrookpr.com)
 Walbrook PR Limited
 Paul McManus / Phillip Marriage  Mob: +44 (0)7980 541 893 / +44 (0)7867 984 082

 Alice Woodings                   +44 (0)7407 804 654

 

 

About Abingdon Health plc

 

Abingdon Health is a leading lateral flow contract development and
manufacturing organisation ("CDMO") offering its services to an international
customer base across industry sectors that include clinical, animal health,
plant health, and environmental testing. Abingdon Health has the internal
capabilities to take projects from initial concept through to routine and
large-scale manufacturing; from "idea to commercial success."

 

The Company's CDMO division offers product development, regulatory support,
technology transfer and manufacturing services for customers looking to
develop new assays or transfer existing laboratory-based assays to a lateral
flow format. Abingdon Health aims to support the increase in need for rapid
results across many industries and locations and produces lateral flow tests
in areas such as infectious disease, clinical testing including companion
diagnostics, animal health and environmental testing. Faster access to results
allows for rapid decision making, targeted intervention and can support better
outcomes.

 

Abingdon Health's Abingdon Simply Test range of self-tests is an ecommerce
platform that offers a range of self-tests to empowers consumers to manage
their own health and wellbeing. The Abingdon Simply Test
(http://www.abingdonsimplytest.com) ecommerce site offers consumers a range of
information to support them in making informed decisions on the tests
available. In addition, the site provides Abingdon's contract services
customers with a potential route to market for self-tests. The Abingdon Simply
Test range is also sold through international distributors and through other
channels in the UK and Ireland such as pharmacy chains.

 

Founded in 2008, Abingdon Health is headquartered in York, England.

 

For more information visit: www.abingdonhealth.com
(http://www.abingdonhealth.com/)

 

 

This information is provided by Reach, the non-regulatory press release distribution service of RNS, part of the London Stock Exchange. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

Reach is a non-regulatory news service. By using this service an issuer is confirming that the information contained within this announcement is of a non-regulatory nature. Reach announcements are identified with an orange label and the word “Reach” in the source column of the News Explorer pages of London Stock Exchange’s website so that they are distinguished from the RNS UK regulatory service. Other vendors subscribing for Reach press releases may use a different method to distinguish Reach announcements from UK regulatory news.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  NRAUPUAGWUPWGBQ